Michael Gold to Alzheimer Disease
This is a "connection" page, showing publications Michael Gold has written about Alzheimer Disease.
Connection Strength
1.213
-
Modeling Alzheimer's disease progression using the disease system analysis approach. Alzheimers Dement. 2012 Jan; 8(1):39-50.
Score: 0.258
-
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010; 30(2):131-46.
Score: 0.242
-
Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease. J Clin Psychiatry. 2007 Mar; 68(3):430-8.
Score: 0.190
-
A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer's Disease: Towards a More Continuous Approach. J Alzheimers Dis. 2022; 86(2):511-524.
Score: 0.133
-
A multi-center randomized proof-of-concept clinical trial applying [?8F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J Alzheimers Dis. 2010; 22(4):1241-56.
Score: 0.058
-
Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005; 20(2-3):120-32.
Score: 0.042
-
No association between the NOS3 codon 298 polymorphism and Alzheimer's disease in a sample from the United States. Ann Neurol. 2000 May; 47(5):687.
Score: 0.030
-
Gender-specific association of the angiotensin converting enzyme gene with Alzheimer's disease. Neurosci Lett. 2000 Feb 25; 280(3):215-9.
Score: 0.029
-
Alzheimers disease is not associated with the hypertension genetic risk factors PLA(2) or G protein beta3, either independently or interactively with apolipoprotein E. Am J Med Genet. 1999 Oct 15; 88(5):465-8.
Score: 0.028
-
The alpha-2 macroglobulin gene is not associated with Alzheimer's disease in a case-control sample. Neurosci Lett. 1999 Aug 06; 270(3):133-6.
Score: 0.028
-
No genetic association between polymorphisms in the Tau gene and Alzheimer's disease in clinic or population based samples. Neurosci Lett. 1999 May 14; 266(3):193-6.
Score: 0.028
-
The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism. Neurosci Lett. 1998 Aug 14; 252(2):95-8.
Score: 0.026
-
The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations. Neurosci Lett. 1998 Jun 19; 249(2-3):115-8.
Score: 0.026
-
No interaction between the APOE and the alpha-1-antichymotrypsin genes on risk for Alzheimer's disease. Am J Med Genet. 1997 Apr 18; 74(2):192-4.
Score: 0.024
-
No association between the intronic presenilin-1 polymorphism and Alzheimer's disease in clinic and population-based samples. Am J Med Genet. 1997 Apr 18; 74(2):202-3.
Score: 0.024
-
No association between the very low density lipoprotein receptor gene and late-onset Alzheimer's disease nor interaction with the apolipoprotein E gene in population-based and clinic samples. Genet Epidemiol. 1997; 14(3):299-305.
Score: 0.023
-
Familial and population-based studies of apolipoprotein E and Alzheimer's disease. Ann N Y Acad Sci. 1996 Dec 16; 802:16-26.
Score: 0.023